Soleno Therapeutics Inc.
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Corrects Previous Disclosure
Summary
Soleno Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023, highlighting a net loss of approximately $11.3 million for Q4 2023 and $39.0 million for the full year, compared to $5.5 million and $24.1 million respectively in the same periods of 2022. The company also corrected a scrivener's error in its previously disclosed financial results, adjusting general and administrative expenses for Q4 2023 from $4,410 to $4,140. Soleno continues to advance its lead product candidate, DCCR, for the treatment of Prader-Willi Syndrome (PWS), with plans to submit a New Drug Application (NDA) in mid-2024. Additionally, the company strengthened its leadership team and raised approximately $129 million from a public offering in October 2023.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement